Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States

References

• Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65(1):333–347. doi:10.1146/annurev-med-060512-150254
   PubMedGoogle Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi:10.1056/NEJMoa1215134
   PubMed Web of Science ®Google Scholar
• U. S. Food and Drug Administration. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma
   Google Scholar
• U. S. Food and Drug Administration. FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-second-line-treatment-large-b-cell-lymphoma.
   Google Scholar
• U. S. Food and Drug Administration. FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma.
   Google Scholar
• BioPharma Dive BJ. Hospital docs weigh in on CAR-T reimbursement: ‘It’s very complicated’. Accessed 4/17, 2023. https://www.biopharmadive.com/news/car-t-hospital-reimbursement-cancer-ash18/543626/.
   Google Scholar
• Kamal-Bahl S, Puckett JT, Bagchi I, et al. Barriers and solutions to improve access for chimeric antigen receptor therapies. Immunotherapy. 2022;14(9):741–753. doi:10.2217/imt-2022-0037
   Web of Science ®Google Scholar
• Mohammadi I, Purdum AG, Wong AC, et al. Cost and healthcare utilization in relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis of medicare beneficiaries receiving chimeric antigen receptor T-cell Vs. Autologous and allogeneic hematopoietic cell transplants. Blood. 2020;136(Supplement 1):4–4. doi:10.1182/blood-2020-134828
   PubMedGoogle Scholar
• Chen L, Xie J, Wu A, et al. Resource use and costs in patients with relapsed/refractory diffuse large C-cell lymphoma who initiated a third-line therapy in the post CAR-T era: a longitudinal outlook. J Clin Oncol. 2021;39(15_suppl):e19560–e19560. doi:10.1200/JCO.2021.39.15_suppl.e19560
   Web of Science ®Google Scholar
• Premier Healthcare Database White Paper: Data that informs and performs. March 2, 2020., Available at: https://learn.premierinc.com/white-papers/premier-healthcare-database-whitepaper.
   Google Scholar
• Jeong IG, Khandwala YS, Kim JH, et al. Association of Robotic-Assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015. Jama. 2017;318(16):1561–1568. doi:10.1001/jama.2017.14586
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771–783. doi:10.1056/NEJMoa0707571
   PubMed Web of Science ®Google Scholar
• Kadri SS, Gundrum J, Warner S, et al. Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations. Jama. 2020;324(24):2553–2554. doi:10.1001/jama.2020.20323
   PubMed Web of Science ®Google Scholar
• Moon RC, Mackey RH, Cao Z, et al. Is coronavirus disease 2019 (COVID-19) less deadly now? Trends in in-hospital mortality among hospitalized COVID-19 patients in the United States. Clin Infect Dis. 2022;74(12):2238–2242. doi:10.1093/cid/ciab830
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines® insights: b -cell lymphomas, version 5.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(11):1218–1230. doi:10.6004/jnccn.2021.0054
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi:10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar
• Prasad A, Rosenthal NA, Kartashov A, et al. Contemporary trend of acute kidney injury incidence and incremental costs among US patients undergoing percutaneous coronary procedures. Catheter Cardiovasc Interv. 2020;96(6):1184–1197. Nov doi:10.1002/ccd.28824
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics. Inpatient hospital services consumer price index. http://www.bls.gov/cpi/.
   Google Scholar
• Mihaylova B, Briggs A, O'Hagan A, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916. doi:10.1002/hec.1653
   PubMed Web of Science ®Google Scholar
• Cao Z, Villa KF, Lipkin CB, et al. Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation. J Med Econ. 2017;20(8):871–883. doi:10.1080/13696998.2017.1336623
   PubMed Web of Science ®Google Scholar
• Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6(1):93–109. doi:10.1093/biostatistics/kxh020
   PubMed Web of Science ®Google Scholar
• Koyner JL, Mackey RH, Rosenthal NA, et al. Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients. Kidney360. 2023;4(3):316–325. doi:10.34067/KID.0005552022
   Google Scholar
• R Core Team. 2021). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
   Google Scholar
• Ring A, Grob B, Aerts E, et al. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. Ann Hematol. 2022;101(8):1755–1767. doi:10.1007/s00277-022-04881-0
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi:10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Yang H, Bollu V, Lim S, et al. Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% medicare claims database. Leuk Lymphoma. 2022;64(2):339–348. doi:10.1080/10428194.2022.2147395
   PubMed Web of Science ®Google Scholar
• Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenle­cleucel for relapsed/refractory aggressive B-cell lymphomas. Biology of Blood and Marrow Transplantation. 2020/03/01/2020;26(3):S41–S42. doi:10.1016/j.bbmt.2019.12.108
   Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–3128. doi:10.1200/jco.19.02104
   PubMed Web of Science ®Google Scholar
• Chacim S, Monjardino T, Cunha JL, et al. Costs, effectiveness, and safety associated with chimeric antigen receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLoS One. 2022;17(12):e0278950. doi:10.1371/journal.pone.0278950
   PubMed Web of Science ®Google Scholar
• Fiorenza S, Ritchie DS, Ramsey SD, et al. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55(9):1706–1715. doi:10.1038/s41409-020-0956-8
   PubMed Web of Science ®Google Scholar
• Freedman SA, Friedberg WJ. Diffuse large B cell lymphoma (DLBCL): suspected first relapse or refractory disease in medically-fit patients. In: upToDate., Rosmarin AG (Ed), UpToDate, Waltham, MA (Accessed on March 03, 2023).
   Google Scholar
• Perica K, Curran KJ, Brentjens RJ, et al. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at memorial sloan kettering cancer center. Biol Blood Marrow Transplant. 2018;24(6):1135–1141. doi:10.1016/j.bbmt.2018.02.018
   PubMed Web of Science ®Google Scholar
• Tully S, Feng Z, Grindrod K, et al. Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model. J Clin Oncol Clin Cancer Inform. 2019;3:1–9. doi:10.1200/cci.19.00086
   PubMedGoogle Scholar
• Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:1–8. doi:10.1200/edbk_279151
   PubMedGoogle Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/s0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022;28(10):669–676. doi:10.1016/j.jtct.2022.07.011
   PubMedGoogle Scholar
• Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132(Supplement 1):91–91. doi:10.1182/blood-2018-99-114152
   Web of Science ®Google Scholar
• Ibrahim Y-A, Christian C, Peter B, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the european society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316. doi:10.3324/haematol.2019.229781
   PubMed Web of Science ®Google Scholar
• Business Wire. Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma 2023 [Available from: https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma.]
   Google Scholar
• Gajra A, Zalenski A, Sannareddy A, et al. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022;36(3):163–171. doi:10.1007/s40290-022-00428-w
   PubMed Web of Science ®Google Scholar
• Snider JT, McMorrow D, Song X, Diakun D, Wade SW, Cheng P. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma. Clin Ther. 2022;44(4):521–38.
   Google Scholar